General Atorvastatin reduces major cardiovascular events but misses disability-free survival goalBy Healthcare Propulsion StaffAugust 29, 20260 Atorvastatin reduced major cardiovascular events by 30% in older people without known cardiovascular disease, diabetes or dementia, but did not…
General Milvexian fails to reduce cardiovascular events after acute coronary syndromeBy Healthcare Propulsion StaffAugust 29, 20260 Milvexian did not reduce major adverse cardiovascular events compared with placebo after a recent acute coronary syndrome and there was…
General First joint guidelines address cardiovascular events and chronic kidney diseaseBy Healthcare Propulsion StaffAugust 28, 20260 The first-ever European Society of Cardiology Guidelines on the management of cardiovascular disease and chronic kidney disease have been developed…
